Compositions comprising bacterial strains

Abstract

The invention provides compositions comprising one or more bacterial strains for treating preventing diarrhea and/or constipation.

1 .- 34 . (canceled) 
     
     
         35 . A method of treating or preventing diarrhea associated with Enterobacteriaceae infection in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a bacteria strain of the genus  Blautia,    wherein the bacteria strain comprises a 16S rRNA gene having at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO:5,   wherein the subject has an Enterobacteriaceae infection, and wherein the administering is effective to treat or prevent diarrhea in the subject.   
     
     
         36 . The method of  claim 35 , wherein the administering reduces the level of Enterobacteriaceae in the gastrointestinal tract. 
     
     
         37 . The method of  claim 35 , wherein the pharmaceutical composition comprises from about 1×10 9  to about 1×10 12  colony forming units (CFU) of the bacteria strain. 
     
     
         38 . The method of  claim 35 , wherein the pharmaceutical composition comprises from about 1×10 3  to about 1×10 11  CFU per gram (CFU/g) of the bacteria strain with respect to a total weight of the pharmaceutical composition. 
     
     
         39 . The method of  claim 35 , wherein the Enterobacteriaceae is  E. coli.    
     
     
         40 . The method of  claim 35 , wherein the subject is a human. 
     
     
         41 . The method of  claim 35 , wherein the pharmaceutical composition is formulated for oral administration. 
     
     
         42 . The method of  claim 35 , wherein the pharmaceutical composition is formulated for rectal administration. 
     
     
         43 . The method of  claim 35 , wherein the pharmaceutical composition is formulated as a suppository. 
     
     
         44 . The method of  claim 43 , wherein the suppository comprises cocoa butter, suppocire, witepsol, glycero-gelatin, polyethylene glycol, or soap glycerin. 
     
     
         45 . The method of  claim 35 , wherein the bacteria strain is lyophilized. 
     
     
         46 . The method of  claim 35 , wherein the pharmaceutical composition further comprises a lyoprotectant. 
     
     
         47 . The method of  claim 35 , wherein the subject is currently receiving an antibiotic treatment. 
     
     
         48 . The method of  claim 47 , wherein the antibiotic is fluoroquinolone, azithromycin, ciprofloxacin or rifaximin. 
     
     
         49 . The method of  claim 35 , wherein the bacteria strain comprises a 16S rRNA gene having at least 98% sequence identity to the polynucleotide sequence of SEQ ID NO:5. 
     
     
         50 . The method of  claim 35 , wherein the bacteria strain comprises a 16S rRNA gene having the polynucleotide sequence of SEQ ID NO:5. 
     
     
         51 . The method of  claim 35 , wherein the pharmaceutical composition comprises a single bacteria strain of the genus  Blautia.    
     
     
         52 . The method of  claim 35 , wherein the pharmaceutical composition comprises the bacteria strain of the genus  Blautia  as part of a microbial consortium. 
     
     
         53 . The method of  claim 35 , wherein the bacteria strain is of the species  Blautia hydrogenotrophica.    
     
     
         54 . The method of  claim 35 , wherein the bacteria strain is the strain deposited under accession number DSM 10507/14294.